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The present narrative review is the first in a series of reviews about the appropriate conduct
in substance-assisted psychotherapy (SAPT). It outlines a current perspective onpreconditions
and theoretical knowledge that have been identified as valuable in the literaturefor appropriate
therapeutic conduct in SAPT. In this context, considerations regarding ethics and the spiritual
emphasis of the therapeutic approaches are discussed. Further, current methods, models,
and concepts of psychological mechanism of action and therapeutic effects of SAPT are
summarized, and similarities between models, approaches, and potential mediators for
therapeutic effects are outlined. It is argued that a critical assessment of the literature might
indicate that the therapeutic effect of SAPT may be mediated by intra- and interpersonal
variables within the therapeutic context rather than specific therapeutic models per se. The
review provides a basis for the development and adaptation of future investigations, therapeutic
models, training programs for therapists, and those interested in the therapeutic potential of
SAPT. Limitations and future directions for research are discussed.
Keywords: substance-assisted psychotherapy, psychotherapy, psychedelics, therapeutic rationale, therapeutic
conduct

INTRODUCTION
Research on psychotherapy utilizing psychoactive substances, subsequentially referred to as
substance-assisted psychotherapy (SAPT), has been re-established in the 21st century. This
renewed interest has been referred to as the “psychedelic renaissance” (Sessa, 2012). It has
followed a period in which these substances were stigmatized, not due to their international
prohibition in 1971 since the early evidence collected on SAPT suggested psychedelics could
be effective in treating a variety of mental health conditions; but rather, due to the circumstances
in which they were prohibited (Grinspoon and Bakalar, 1979). With public and professional
interest in SAPT rapidly growing, this narrative review presents the perspective on the necessary
preset (i.e., valuable preconditions and knowledge) for practicing SAPT that has been identified
in the current literature on the topic.
The recent growth in research has included clinical trials demonstrating the safety and
efficacy of this approach for treatment refractory post-traumatic stress disorder (PTSD;
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Mithoefer et al., 2019), alcohol dependence (Bogenschutz et al.,
2015), as well as anxiety and depression associated with end
stage cancer (Agin-Liebes et al., 2020). Open label trials
have also indicated that psychedelic-assisted psychotherapy
could be effective in treating obsessive–compulsive disorder
(Moreno et al., 2006), treatment-resistant depression (TRD;
Carhart-Harris et al., 2016), and nicotine dependence (Johnson
et al., 2017). Although there is recent progress in recording
the safety and effectiveness of these approaches paving the
way for their potential implementation and application in
clinical practice (e.g., Kargbo, 2020; Nichols, 2020), the
mechanisms responsible for therapeutic change across different
psychotherapeutic approaches are still not fully understood.
Classic psychedelics (e.g., LSD, psilocybin, DMT and
mescaline) are regarded as non-addictive and do not appear
to present an independent risk factor for mental health problems
(Krebs and Johansen, 2013; Johansen and Krebs, 2015; Hendricks
et al., 2015). Meanwhile, other psychoactive substances with
subjective effects that are similar to psychedelics, such as
ketamine (Krupitsky and Grinenko, 1997; Serafini et al., 2014),
MDMA (Thal and Lommen, 2018) and ibogaine (Alper, 2001),
are being investigated as for their potential use in SAPT.
Classic psychedelics and MDMA have been found to produce
acute and persistent positive personality changes (Bouso et al.,
2018) and improved well-being in healthy individuals (Elsey,
2017; Jungaberle et al., 2018). These substances have been
linked to heightened mindfulness (Soler et al., 2016, 2018),
a sense of connection to nature (Forstmann and Sagioglou,
2017), creativity (Kuypers et al., 2016; Uthaug et al., 2018;
Mason et al., 2019), and openness (Liechti et al., 2017). Many
researchers have called for more extensive research into the
potential of the clinical applications of these substances,
particularly in respect to the current mental health crisis
(see Belouin and Henningfield, 2018; Schenberg, 2018) and
the limited awareness of their potential amongst health care
professionals (Barnett et al., 2018).
It is becoming increasingly apparent that the potential
effects of SAPTs are dependent on several contextual factors,
including psychological preparation prior to the experience
(Johnson et al., 2008), extra-pharmacological manipulations
in the form of specific music playlists (Kaelen et al., 2018),
and psychological integration subsequent to the experience
(Hartogsohn, 2017; Richards, 2017; Carhart-Harris et al., 2018;
Garcia-Romeu and Richards, 2018). Key components that
meditate the therapeutic alliance (e.g., unconditional acceptance
and therapeutic presence) and have been shown to be strong
predictors of outcome in traditional psychotherapy (Frank
and Frank, 1991; Geller and Greenberg, 2012; Norcross and
Lambert, 2018), are also likely play a vital role in SAPT
(Greer and Tolbert, 1998; Garcia-Romeu and Richards, 2018).
In this narrative review, we will summarize valuable
considerations, methods, models, and current (theoretical)
concepts regarding the psychological mechanism of action and
therapeutic effects of SAPT that are identified in the literature.
Thereby, we highlight similarities between models and approaches
to outline potential mediators for therapeutic effects. Further,
we critically discuss literature indicating that various schools
Frontiers in Psychology | www.frontiersin.org

of psychotherapy may translate and incorporate their approaches
to SAPT. This article is intended to provide the preface (or
preset) to a series of systematic and narrative reviews examining
each stage of the SAPT treatment process, by outling the
valuable prerequise knowledge for psychotherapists interested
in practicing SAPT. In doing so, we have not considered the
additional medical training and knowledge required to provide
SAPT (e.g., physiological conditions and concomitant
mediucations that would contraindicate SAPT) in this article
since it is not within our scope of clinical practice.

ETHICAL CONSIDERATIONS
There are strict conditions and frameworks required by ethical
committees of universities and research institutes currently
investigating SAPT, extensive bureaucratic and jurisdictional
exchange with government institutions, and cautious storage,
documentation, and safety procedures are necessary to conduct
research in this field (Strassman, 2001; Johnson et al., 2008;
Bogenschutz, 2013; Nutt et al., 2013). While standard ethical
guidelines apply to SAPT, additional considerations are vital.
The Council on Spiritual Practices offers a code of ethics for
spiritual guides that provides a framework for guiding people
through exceptional states of consciousness that can be transferred
to therapeutic sessions with psychoactive substances (Jesse, 2001).
Therein, it is firmly highlighted that it is crucial for therapists
to be well-intended and empathetic towards their clients due
to augmented transference, counter-transference, and suggestibility
(Leary, 1961; Fadiman, 2011; Carhart-Harris et al., 2015). As
such, risks (both physical and psychological) should be discussed,
preventive measures should be taken, and the client should
be educated on the comparatively rapid transformative potential
of the therapy (see Griffiths et al., 2006).
Therapists should be aware of the possibility of substanceoccasioned uncomfortable material (sexual, or traumatic), and
be prepared to respond to this using methods and techniques
for which they are qualified through education, training, and
experience (Grof, 2000; Phelps, 2017). In these situations,
therapists need to simultaneously help clients process this
material and prevent colluding with clients in acting out
inappropriately (see Grof, 2000). Therapists and clients should
agree upon limits on behaviors prior to the session. Such
limitations could include outlining the parameters for appropriate
touch, prohibiting self-harm, violence against facilitators and
others, destruction of property, and sexual acting out
(Mithoefer, 2017).
Increased vulnerability to suggestions and manipulations
due to the heightened suggestibility in psychedelic states was
identified in healthy volunteers after the administration of LSD
(Carhart-Harris et al., 2015). This vulnerability, combined with
increased attribution of certain ideas holding personal meaing
or perceiving the ideas and contents experienced under the
influence of psychedelics to hold greater noetic truth value in
both healthy and clinical samples (Timmermann et al., 2020),
may lead to reduced agency and judgment when compared
to regular psychotherapy sessions. Even simple misunderstandings
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might be more likely to occur and the validation and mediation
of the content and knowledge experienced in these states raises
important ethical considerations: the increased risk of iatrogenic
complications (e.g., false memory syndrome; Pope, 1996) through
induced noetic feelings of revelation. Timmermann et al. (2020)
propose a pragmatic framework founded on an ethical approach
embedding these experiences within larger cultural- and historical
contexts while considering their intersubjective character. They
stress the importance of validation based on empathy by an
experienced therapist to facilitate appropriate processing and
integration of these experiences while considering aforementioned
challenges. There is also an increased importance for therapists
to be aware of the limitations on scope of practice required
by most psychotherapy regulatory bodies, including preventing
clients from being exploited, and therapists having an awareness
of their own limitations, values, needs, and beliefs. Most
importantly, therapists should be open for regular peer-review
and seek council and feedback from other practitioners as
required by most professional bodies. This is of utmost importance
in SAPT because of the strict legal framework that must
be considered and the aforementioned elevated potential for
misperception and misjudgment.
The need for therapists’ self-experience with altered states of
consciousness and substances that are administered in SAPT is
controversial. For example, Forstmann and Sagioglou (2021) found
that the perception of a reserachers’ integrity and quality of their
research by psychedelic naïve participants was reduced if the
researcher self-admitted substance use (Forstmann and Sagioglou,
2021). While there will likely be a continuum amongst therapists
engaged in SAPT clinical trails, ranging from those without any
personal experiences to those with a vast amount of experience
across substances and settings, open discussion of these experiences
can be constrained for fear of personal, professional, and sometimes
legal consequences (Nielson and Guss, 2018; Ross et al., 2020).
Some practitioners in the field regard personal experiences with
these substances as essential in order to emphasize with the client’s
experiences (Metzner, 1998; Bogenschutz, 2013; Bogenschutz and
Forcehimes, 2017) and in certain countries, such as Switzerland,
personal experience is required for therapists to work with clients
in SAPT settings (Grof, 2000; Strassman, 2001). However, personal
experiences may lead some therapists to become less curious
about the client if they believe that their clients’ experience will
be similar to their own (Bogenschutz, 2013; Bogenschutz and
Forcehimes, 2017). Thus, personal experience is a double edged
sword that may be a potential confound to research and SAPT,
though has not yet been empirically investigated (Nielson and
Guss, 2018). Also, in line with standard ethical guidelines, we believe
that therapists should not take any mind-altering substances before
or during therapy sessions, regardless of whether they are providing
SAPT or regular psychotherapy.

dilation and ego dissolution (Griffiths et al., 2006, 2008; MacLean
et al., 2011). They may be compared to non-substance-induced
personal encounters with God, a divine entity, or Ultimate
Reality (Griffiths et al., 2019). Such research using psychometric
outcome measures was first conducted at Harvard overy 50
years using a 43-item tool develop by Pahnke (1969). More
recent research has typically used a 30 item iteration of this
tool (the revised Mystical Experience Qusetion; MacLean et al.,
2012), which appears to have more robust psychometric properties
(Barrett et al., 2015).
Since this therapeutic experience may be regarded as one
of the most meaningful experiences of the clients’ lives (Griffiths
et al., 2006, 2008; MacLean et al., 2011; Preller et al., 2017;
Schmid and Liechti, 2018), Garcia-Romeu and Richards (2018)
have proposed that therapists consider treating it accordingly
throughout the entire therapeutic process. Adamson and Metzner
(1988) have claimed that even though therapists may not
be religious themselves and exclude these aspects from their
usual work, spiritual perspectives on the experience that may
arise in the clients engaged in SAPT should be respected and
supported. While an emphasis on specific religious systems
has been discouraged by Grof (2000), he has proclaimed it
as useful to focus on the awareness of the aesthetic aspects
of the world, basic philosophical questions of life, and the
recognition of spiritual dimensions of existence in a non-specific
way. Meanwhile, Stolaroff (2004) has propsoed that unless
clients are using the word “spiritual,” it might be advisable to
avoid labels, due to the danger of enhanced suggestibility.
Importantly, avoiding the psychological blockages and focusing
on the repetition of spiritual experiences (i.e., spiritual bypassing),
may constitute a pitfall for therapeutic progress, with Frecska
et al. (2016) cauitioning that it may result in avoidance of
the real psychological issues and an unhealthy relationship
with spiritual aspects of substance-induced experiences.
As outlined below, therapeutic approaches that integrate
contemplative spiritual practices like third wave behavior therapies
(TWBTs) have been identified as valuable frameworks for SAPT
in the literature (Walsh and Thiessen, 2018). Recent research
investigating the interaction between meditation and psilocybin
found potential synergistic effects of meditation practices and
mystical experiences or ego dissolution occasioned by psilocybin
(Griffiths et al., 2018; Smigielski et al., 2019). This finding
may suggest that the development of mindfulness- or other
spiritual or meditative practices through the preparatory and
integration stages of therapy could potentiate the treatment
effects (Walsh and Thiessen, 2018).

MECHANISM OF ACTION AND
THERAPEUTIC EFFECTS OF
SUBSTANCE-ASSISTED
PSYCHOTHERAPY

SPIRITUAL EMPHASIS OF THE
THERAPY

It is predominantly believed that the therapeutic effects of substanceassisted treatments are a combination of the psychopharmacological
effects of the substance (e.g., see Carhart-Harris et al., 2014;

Substance-occasioned spiritual or mystical experiences have
been described as ineffable, noetic, and sacred, involving time
Frontiers in Psychology | www.frontiersin.org
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Carhart-Harris and Friston, 2019; Preller et al., 2019), which
influence the client’s intrapsychic experience, but also the shared
interpersonal experience between client and therapist (Adamson
and Metzner, 1988), the mindset of the client and the therapist,
and successful psychotherapeutic integration of the experience
(Mithoefer, 2017; Bogenschutz et al., 2018; Malone et al., 2018).
Thereby, the quality, intensity, and duration of challenging parts
of the acute psychedelic experience may be key mediators for
the therapeutic outcome (Carbonaro et al., 2016; Roseman et al.,
2018). However, the acute and long-term or persistent effects
(more relevant for treatment effects) differ substantially
(Carhart-Harris et al., 2016), so the specific psychological
mechanisms that account for their therapeutic efficacy are still
not comprehensively understood. Various acute and persistent
effects of psychedelics and entactogens were outlined by Jungaberle
et al. (2018) and include, amongst others, positive effects on wellbeing, mood, empathy, cognitive flexibility, self-transcendence, and
openness. However, individual experiences might be extremely
variable and generalizations based on single sessions and small
sample sizes are problematic (Grof, 2000; Bogenschutz et al., 2018)
due to different personality structures of the client (Sandison and
Whitelaw, 1957; Cohen, 1960; Gucker, 1963) amongst other
individual differences. Consequently, attempts to depict and
generalize the psychological mechanisms of action rendering SAPT
an effective treatment option for certain disorders draw on similar
terminologies to frame distinct theoretical concepts. These concepts
may not be mutually exclusive (i.e., they tend to partially intersect).
Thus, significant differences seem to be more evident in the
theoretical foundations the concepts stem from rather than their
conclusions. In this section, we have attempted to merge these
concepts as derived from diverse models into meaningful clusters.
We have also not attempted to distinguish the moderating factor
of which psychedelics could differentially contribute to each
mechanism, as the literature at present does not seem advanced
enough for such an analysis.

and their therapists’ notes, Malone et al. (2018) found that
psilocybin may support clients in gaining insight regarding
the root cause of their issues or disorders due to the personalized
nature of the subjective experiences that seems to be tailored
to individual psychological needs.
This hypothesis is supported from the results of a pilot
study of 13 participants (N = 9 with diagnoses of substance
abuse and/or dependence) in which self-report measures of
the Purpose of Life Test significantly increased at three and
nine-month follow ups after treatment with Ayahuasca (Fernández
et al., 2013). In another study, 36 participants without prior
experience with psychedelics received psilocybin or placebo
in a double-blind counterbalanced design (Griffiths et al., 2006).
In a 14-month follow-up, 58% of the participants assessed the
experience as one of the five most personally meaningful
experiences of their lives with 64% indicating persistent increases
in life-satisfaction or well-being (Griffiths et al., 2008). Similarly,
13 of 15 (i.e., 86%) participants in a one-year follow-up of a
psilocybin-facilitated smoking cessation trial rated the experience
amongst the five most meaningful experiences of their lives
(Johnson et al., 2017) and 10 of 14 (i.e., 71%) healthy volunteers
in an LSD study rated the experience as one of the ten most
meaningful experiences of their lives at one-year follow-up
(Schmid and Liechti, 2018). Personally meaningful and emotional
experiences with mystical qualities or ego dissolution are now
thought to have causal links to persisting positive effects
(Bogenschutz and Ross, 2016).

Awe and Peak-Experiences

Awe can be defined as an emotion that is associated with
profound pleasure bordering on fear while appreciating vastness
(perceiving various stimuli as larger than the self) and
accommodation (the need to revise mental structures to integrate
novel experiences and perspectives; Keltner and Haidt, 2003).
It is hypothesized that the profound awe that characterizes
peak experiences occasioned by psychedelics may require
habituated mental structures to accommodate to integrate and
account for these novel perceptions and experiences. This
process of cognitive re-accommodation may result in
disorientation, fear, ego dissolution, and subsequent feelings
of ultimate knowledge and enlightenment – once new information
can be assimilated through the adaptation of mental structures
(Hendricks, 2018). As a result, the profound feeling of awe
may encourage one to superordinate the social collective to
one’s individual needs, i.e., decrease egocentrism (Bai et al.,
2017), and thus facilitate cooperation (Gowdy and Krall, 2015),
shift attention to the presence while expanding experience of
time (Rudd et al., 2012), and decrease tolerance for uncertainty
which in turn elevates the inclination to acknowledge the
influence of supernatural agents in experiences (Valdesolo and
Graham, 2014). Thus, the sense of heightened connectedness
or oneness with others and the universe (Carhart-Harris et al.,
2018), and the shift of attention towards the collective and
away from the self are theorized to constitute the positive
treatment effects of psychedelics across a range of disorders
(see Hendricks, 2018).

Personal Significance, Insights, and
Meaningfulness

Early psychedelic research assumed that a heightened sense
of significance and meaningfulness (also described as
prolonged “eureka” experience) under the influence of certain
substances contributed to the therapeutic effects (Ludwig and
Levine, 1965b). Material encountered during substance-assisted
sessions is usually personal and uniquely meaningful (Griffiths
et al., 2006, 2008; MacLean et al., 2011; Preller et al., 2017;
Schmid and Liechti, 2018) and relevant to the facilitation
of personal growth in each client (Cutner, 1959; Shanon, 2003;
Bogenschutz et al., 2018).
The importance of personal meaning has been highlighted
in various empirical studies. In a randomized, double-blind,
active placebo-controlled study, 29 participants experiencing
cancer-related anxiety and depression received a single-dose
of psilocybin in conjunction with psychotherapy (Ross et al.,
2016). Through synthesizing prior qualitative analyses of
interviews with these participants (Belser et al., 2017; Swift
et al., 2017), with a qualitative analysis of their written narratives
Frontiers in Psychology | www.frontiersin.org
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Reconditioning

to different contexts (Franquesa et al., 2018). Subjective feelings
of increased connection with oneself were linked to positive
treatment effects of Ayahuasca for substance use in an
observational study of 12 participants in a retreat combining
4 days of group counseling and two Ayahuasca sessions
(Thomas et al., 2013).
Ayahuasca and psilocybin were both shown to have acute
and prolonged effects on cognitive-thinking style (Kuypers
et al., 2016; Uthaug et al., 2018; Mason et al., 2019) and
positive treatment effects of psilocybin may results from shifts
in self-representation (Smigielski et al., 2019). Neurocognitively,
these shifts may be linked to enhanced cognitive flexibility
(Gallimore, 2015) and altered neural connectivity (Tagliazucchi
et al., 2016; Carhart-Harris et al., 2017; Preller et al., 2019).
This may also be reflected in changes in personality measures
like decreased neuroticism and increased conscientiousness and
extraversion (i.e., openness) that have been observed in an
open-label trial of 20 participants with moderate to severe
TRD (Erritzoe et al., 2018).
Qualitative data (Watts et al., 2017) from aforementioned
open-label study investigating psilocybin for TRD (CarhartHarris et al., 2016) suggests that psychedelics combined with
psychotherapy may increase psychological flexibility more than
psychotherapy itself (Watts and Luoma, 2020). It is suggested
that increased psychological flexibility may mediate therapeutic
effects (Hayes et al., 2012) in Acceptance and Commitment
Therapy (ACT). This has led some authors (e.g., Sloshower
et al., 2020; Wolff et al., 2020) to suggest that ACT might
exhibit synergistic therapeutic mechanisms with SAPT. However,
these speculations have yet to be verified.

One potential mechanism of change in SAPT is the breaking
of previously rigid maladaptive emotional and cognitive patterns,
prior to them being reformed and reintegrated in a new
structure (Frecska, 2011). This has been referred to as
“restructuring,” “retraining” or “reconditioning” treatment
(Spencer, 1964). The process can be seen as a “secure form
of regression” (Frecska, 2011), in which old associations are
broken down and unlearned. Thus, previously frightening stimuli
could lose their association with threat, and become deconditioned,
before being reintegrated in a less problematic way. This has
also been described as “de-patterning” (Gasser et al., 2015).
Neuroscientific evidence suggests that hyperexcitation in layer
V pyramidal neurons mediated by the 5-HT2A agonism of
psychedelics may disrupt fixated and conditioned cognitions,
psychological habits, and constraints on internal generative
models (Swanson, 2018). Disinhibition of these neurons may
reduce the rigidity of higher-level beliefs (in a hierarchical
predictive processing model) making them more receptive for
bottom-up prediction errors (Carhart-Harris and Friston, 2019).
Thereby, prior fixed beliefs may be more easily challenged and
restructured by novel information. This might be reflected by
lasting changes in attitudes (i.e., increased openness and
extraversion and decreased neuroticism; Erritzoe et al., 2018)
and beliefs in individuals who used psychedelics (Nour et al.,
2017; Jungaberle et al., 2018).

Perspective-Shifts and Cognitive Flexibility

Another proposed mechanism of action is perspective-shifts or
cognitive flexibility. Seemingly, this mechanism can be interpreted
as a combination of a restructuring or shifting of pre-existing
concepts through experiences that carry emotional and/or
intellectual value (see Section "Awe and Peak-Experiences"). New
perspectives and insights might be gained and more rapidly
accepted because of a novel sense of emotional and intellectual
appreciation occasioned by the substance (Ludwig and Levine,
1965a). Some authors suggest that processing of significant
emotional or intellectual content, combined with loosened ego
functions in an altered emotional state, may allow for a reduction
of ruminations and egocentricity (Northoff, 2007; Pizzagalli,
2011) wherein novel perspectives may be gained (Leuner, 1967;
Carhart-Harris et al., 2014) and problems may be appreciated
for their true significance (Hofmann and Ott, 1980). The potential
for a client to experience an alternative view of themselves has
been referred to as “stripping away layers of onions” by some
therapists (Cattell, 1957, p. 227). Gasser et al.'s (2015) mixed
methods data from 10 participants who received LSD-assisted
psychotherapy suggest that amongst other variables, the cognitive
experience (i.e., altered cognitive associations allowing for novel
perspectives on intra- and interpersonal problems and
relationships) mediates positive outcomes.
In a phenomenological discussion of the Ayahuasca
experience, Shanon (2003), reported shifts in the locus of
consciousness, self-consciousness, and personal identity (i.e.,
positive self; see Griffiths et al., 2008) that may result in
heightened cognitive flexibility and support the adaptation
Frontiers in Psychology | www.frontiersin.org

Mindfulness and Acceptance

Mindfulness and acceptance are important aspects of TWBT
that share conceptual links and presumptions with the mechanisms
outlined above. Namely, Wolff et al. (2020) proposed that shifts
from experiential avoidance to acceptance (which is closely
related to mindfulness-practices and a mediator of therapeutic
effects in TWBTs) may be facilitated by the relaxation or
disinhibition of higher level avoidance-related beliefs (see Sections
“Reconditioning” and “Perspective-Shifts and Cognitive
Flexibility”), elicitation and intensification of private events (see
Section “Personal Significance, Insights, and Meaningfulness”),
and operant conditioning of acceptance. During substance-assisted
experiences, avoiding aversive aspects of the experience may
increase adverse responses, while acceptance of the experiences
may result in more rewarding responses (this was termed
“avoidance sensitivity”). This results in the operant conditioning
of acceptance instead of avoidance. The conditioned openness
and acceptance may allow for exposure and consideration of
private events that would otherwise be avoided. As a result,
previously held beliefs may be revised during the relaxation
of avoidance-related beliefs since this state allows for strong
experiential contradictions to negative expectancies, i.e., the
experience of oceanic boundlessness, blissful ego dissolution,
and long-term increases in well-being (Wolff et al., 2020).
Substance-induced dissociation from one’s learned roles and
habits coupled with a conflict-free state of being may foster
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acceptance of oneself. This hypothesis is supported by an
independent group (N = 20 participants) self-report study
comparing four consecutive Ayahuasca sessions with an eightweek mindfulness-stress reduction (MBSR) course (Soler et al.,
2018). Results indicated that Ayahuasca and MBSR led to
comparable increases in acceptance on the Non-Judging Subscale
of the Five Facet Mindfulness Questionnaire. Meanwhile, a
thematic analysis of semi-structured interviews of 20 participants’
accounts of an open-label trial of psilocybin for TRD at 6
months follow-up found change processes from disconnection
(from the self, fellow human beings, and the world) to connection
and from emotional avoidance to acceptance (Watts et al., 2017).
The potential for more open exploration of psychodynamic
connections has been noted in early psychedelic research
(Hausner and Dolezal, 1963). Further, decentering – observing
one’s feelings and thoughts in a detached manner (Kerr et al.,
2011) – was positively associated with Ayahuasca use in a
self-report study of 41 participants without prior experience
with the substance and 81 experienced participants (Franquesa
et al., 2018). In a randomized, double-blind, placebo-controlled
study of 38 participants in a mindfulness retreat, a single
psilocybin experience was linked to alterations in mood, social
behavior, spirituality, and attitudes about life (Smigielski et al.,
2019). Long-term increases in mindfulness following a single
dose of psilocybin in ten psilocybin-naïve participants persisted
for at least 3 months, even without explicit mindfulness training.
This increase in mindfulness may represent a key mechanism
of psilocybin therapy (Madsen et al., 2020). Perceptual
and qualitative changes regarding intra- and interpersonal
consciousness and perceived mindfulness capacities have also
been reported by clients who have received SAPT. Bogenschutz
et al. (2018) have proposed that these changes mediate positive
treatment effects.

and thus result in personal growth regardless of their factual
truth. Similarly, positive effects of abreaction itself under the
influence of certain substances may not be dependent on the
factual truth of the traumatic incident, but rather linked to
the release and re-assessment of trauma-related emotions (see
also Mithoefer, 2017). Curiously, describing specific episodic
content of the psychedelic experience is usually more difficult
than illustrating its cognitive and emotional impact (Bogenschutz
et al., 2018). However, the ineffability of the experience does
not seem to impact its treatment effects or its perceived
meaningfulness (Malone et al., 2018).
In contrast, a placebo-controlled crossover study with
20 healthy participants by Speth et al. (2016) found that
the intensity of the LSD experience was positively correlated
with reduced mental time travel to past events. The authors
argue that mind-wandering to past events may be more
specific but less frequent under LSD. Since ruminating
about past events is linked to reduced happiness
(Killingsworth and Gilbert, 2010), psychedelics may display
similarities to mindfulness-based therapies and thus foster
mental focus on the presence (Shapiro et al., 2006; Soler
et al., 2016, 2018). Gasser et al. (2015) found that, besides
the cognitive experience, the psychodynamic experience
(i.e., emergence of unconscious material into consciousness
and/or reliving of past experiences) and the associated
abreactions and catharsis plus the peak-experiences (i.e.,
ego dissolution, transcendence of time and space, and the
sense of having meaningful novel insights), mediated positive
outcomes in LSD-assisted psychotherapy. Intense emotional
experiences with a state of well-being, pure presence (i.e.,
existing in the here and now), and freedom from past
concerns, guilt, anxiety, and depression combined with the
absence of former tensions had the most significant effect
on clients. Similar experiences of psychodynamic material,
catharsis, connection, love, and self-compassion have
been reported in clinical investigations with psilocybin
(Bogenschutz et al., 2018).
Neuroscientific research suggests that reactivation of past
memories, reconsolidation through incorporations of new
emotional responses related to these memories, and reintegration
through altered behavior in everyday situations may result in
therapeutic change in non-substance assisted therapy (Lane
et al., 2015). It is possible that this similar mechanism contributes
to the change in SAPT as well.

Re-assessment of Memories

Re-experiencing and re-assessing memories under the influence
of certain substances may be another mechanism of action
underlying SAPT that evidences conceptual links to personal
meaning and perspective-shifts. This overlap of mechanisms
may be most evident in the current rationale of the treatment
effects of MDMA-assisted psychotherapy. MDMA increases
cortisol, prolactin, oxytocin, dopamine, norepinephrine, and
serotonin which in turn increases empathy and self-confidence
and reduced feelings of anxiety and depression. This allows
clients to revisit memories and experiences while staying
emotionally engaged without being overwhelmed by negative
emotions which may facilitate memory reconsolidation
(Mithoefer, 2017; Thal and Lommen, 2018).
Based on clinical experiences with clients who have undergone
SAPT with serotonergic psychedelics, Sandison (1959) has
suggested that early memories could be re-experienced in vivid
detail. While these memories are likely a mixture of facts and
fantasies that contain archetypical experiences, these experiences
(Spencer, 1964) may allow for acceptance of more important
emotional connotations (see Sections “Personal Significance,
Insights, and Meaningfulness” and “Mindfulness and Acceptance”)
Frontiers in Psychology | www.frontiersin.org

Dreamlike Qualities

Some psychoactive substances have been associated with
experiences with dreamlike qualities (Jacobs, 1978; Fischman,
1983; Wilkins et al., 2011; Carhart-Harris and Nutt, 2014;
Morris and Wallach, 2014; Kraehenmann, 2017; Kraehenmann
et al., 2017; Rodger, 2018; Sanz and Tagliazucchi, 2018) and
it has been suggested (e.g., Kraehenmann, 2017) that the positive
effects of dreaming on well-being and social functioning may
also be applicable for psychedelics. It is further hypothesized
that altered self-awareness occasioned by some substances may
result from perspective-shifts (from first-person to third-person
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perspective) as is often reported in dreams (Thompson, 2014;
Sanz and Tagliazucchi, 2018). Kraehenmann (2017) proposed
that fear extinction and formation of novel extinction memories
through associative learning in contexts that are not associated
with fear (Nielsen and Levin, 2007; Levin and Nielsen, 2009)
and memory reconsolidation (Schiller et al., 2010; Rolls et al.,
2013) may be related to similar cognitive processes in psychedelics
and dreams. These concepts overlap with deconditioning, and
re-assessment of memories.

to apply to more extraordinary experiences that transcend
interpersonal and verbalizable realms (Grof, 2000). While
psycholytic therapy has influenced current investigations into
therapeutic applications of psychoactive substances, it has not
been employed as the main model in recent clinical trials.
Psychedelic therapy employs high doses of psychoactive
substances that substantially exceed those administered under
psycholytic frameworks (although there is a certain variability
to “low” and “high” doses in reported studies and standardized
“high” and “low” doses are not distinctly defined). It assumes
that the therapeutic effect is produced by the facilitation of
the experience of ego dissolution, also referred to as mysticalor peak experience (Griffiths et al., 2006), thereby transcending
the psychodynamic levels (Grof, 2000). As such, substances
are only used in one to three sessions (guided by the intended
effect and the model of treatment being used), while preparationand integration sessions without substances may or may not
be incorporated (Grof, 2000; Johnson et al., 2008; Bogenschutz,
2013). While psychotherapy is used to maximize the probability
of these experiences to occur (Sherwood et al., 1968; Pahnke
et al., 1971; Grof, 2000; Bogenschutz, 2013), the approach is
not based on classic psychological theories (Leuner, 1967; Majić
et al., 2015). The therapist supports the client in surrendering
to and accepting the experience, but is non-directive and does
not guide the client towards or away from particular experiences
(Pahnke et al., 1971; Rhead et al., 1977; Bogenschutz, 2013).
While music is provided, and therapists observe the client
quietly, verbal interventions are usually not applied during the
peak-substance effects (Bogenschutz, 2013).
Recent research has used the psychedelic approach
(Bogenschutz et al., 2018; Nielson and Guss, 2018) as treatment
for conditions such as addiction disorders and depression
(Johnson et al., 2014; Bogenschutz et al., 2015; Carhart-Harris
et al., 2016; Griffiths et al., 2016). The advantage of the model
is that, due to the high doses used, clients may be less likely
be able to resist the effect of the substances and may be more
likely to completely surrender to the experience. This can allow
for much more substantial effects in a single session compared
to psycholytic therapy, which in turn makes psychological and
environmental factors, i.e., set and setting (see Leary, 1961;
Hartogsohn, 2016) more important for positive therapeutic
effects. Due to its non-directive nature, there is no imperative
for confrontation of psychodynamic conflicts. Instead, a greater
depth, intensity, and spontaneity of the session has been
described (Grof, 2000). Disadvantages may include the risk of
greater emotional upheaval due to the more profound effects
of the substances and greater physiological risks because of
the higher doses (depending on the substance, of course). The
non-directive approach may require the therapist to surrender
to and support the process rather than focus on techniques
and methodologies. It is mentioned that this requires a high
level of expertise and trust in the process and that it is currently
not clear whether improvements and transformations experienced
in psychedelic therapies represent temporary shifts, or if deep
structural psychodynamic changes may be attained. Although
the general expectations may be higher in clients receiving
this approach, it is impossible to guarantee profound experiences

THE DEVELOPMENT OF MODELS FOR
SUBSTANCE-ASSISTED
PSYCHOTHERAPY
In the literature, models of SAPT have been distinguished
primarily according to the dose of the active substance (Mangini,
1998). Low dose SAPTs, or psycholytic therapy (Pahnke et al.,
1971), and high dose SAPTs or psychedelic therapy, sometimes
referred to as psychedelic peak-therapy (Sherwood et al., 1968;
Pahnke et al., 1971; Grof et al., 1973), each attempt to facilitate
different processes. In psycholytic therapy, low to medium doses
of psychoactive substances are used to foster the gradual and
progressive unfolding of various levels of the unconscious
activating and accelerating the process of psychodynamic or
psychoanalytic psychotherapy (Leuner, 1967; Grof, 2000;
Bogenschutz, 2013; Majić et al., 2015). Active verbal
psychotherapy is conducted while the client experiences the
effect of the substance that is used to facilitate revival and
abreaction of past experiences and emotional releases, loosen
defense mechanisms, and deepen introspection and insight.
This is mediated by the therapist’s interpretation of unconscious
material (Eisner and Cohen, 1958; Sandison, 1959; Leuner,
1967; Bogenschutz, 2013). Repeated sessions of SAPT (sometimes
up to 80) are embedded within a psychodynamic or
psychoanalytic psychotherapy process (with significantly more
substance-free than SAPT sessions) stretching over several
months or years (Chandler and Hartman, 1960; Leuner, 1967).
This extensive time-frame renders the comparison to other
models and the isolation of the effects of SAPT-sessions extremely
difficult. Psycholytic therapy was employed as preferred treatment
model for patients with less severe disorders, such as
psychosomatic-, mood-, neurotic-, or personality disorders and
those with an intellectual interest in the therapeutic process
(Grinspoon and Bakalar, 1979; Gasser, 1995; Grof, 2000).
Conveniently, the gradual unfolding of various layers of the
unconscious may allow for unique insights across a variety of
domains. In doing so, clients might achieve an enhanced
understanding of different mechanisms and areas of the mind
through which alterations in behavior or cognition may
be achieved (Grof, 2000). Disadvantages include that this can
require a long duration of treatment, and lower doses may
mean clients ignore or resist more challenging qualities of the
experience. Over the course of therapy, the experience of
transference may inevitably intensify, leading to a deterioration
of symptoms and decompensation. Finally, the conventional
psychodynamic framework of the approach may be challenging

Frontiers in Psychology | www.frontiersin.org
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in all clients, which may lead to disappointment. The mechanism
of action of therapeutic change is still not well understood
and the entire experience can be difficult to capture, quantify,
and integrate (Grof, 2000).
There is considerable overlap between certain fundamental
assumptions of psycholytic and psychedelic models, leading
some authors to suggest the approaches might be blended in
practice to form an hybrid model (Mechaneck et al., 1968;
Metzner, 1998). Non-directive approaches may be used during
intense parts of the session, while discussion, interpretive work
and meaning making may start before the effects of the substance
have ceased completely (Masters and Houston, 1966; Grof,
2000; Bogenschutz and Forcehimes, 2017; Nielson and Guss,
2018). In this case, the adaptability of the therapist based on
the client’s process would be vital.
In current models of MDMA-assisted psychotherapy for
PTSD, this mixed approach has been recommended by Mithoefer
(2017). The substance-assisted sessions are predominantly
client-led; clients are encouraged to lie back with eyeshades
on, focus inwards, and be present with their traumatic memories.
Therapists gently guide clients to consider particular aspects
of their traumas, and if necessary a short general discussion
of the content of the session follows once the effects of the
substance begin to subside (Mithoefer, 2017; Sessa, 2017; Sessa
et al., 2019). There are reported exceptions to this approach.
In a study by Wagner et al. (2019) clients alternated between
spending time focused inside and time focused outside without
headphones and eyeshades spend in conversation with their
partner or therapists. In theory, all models for SAPT may
allow for an incorporation of a variety of different schools
of psychotherapy.

In recent studies, humanistic therapies such logotherapy
(Ross et al., 2016), as well as CBT models (Johnson et al.,
2014; Wolff et al., 2020) and third wave CBT approaches like
ACT (Hayes and Wilson, 1994; Carhart-Harris and Nutt, 2017;
Watts et al., 2017; Sloshower et al., 2020), DBT which has
been described as “behavioral translation of Zen”; Nuys, 2007)
and mindfulness-based cognitive therapy (MBCT; Walsh and
Thiessen, 2018) or motivational enhancement therapy (MET;
Bogenschutz et al., 2015; Sessa et al., 2019) are used or being
proposed as therapeutic frameworks. These therapies each
attempt to target similar mechanisms to those identified as
potential mechanisms in SAPTs.

Insight in Psychodynamic Therapies

Insight has been considered to be a central mechanism of
change, emphasized primarily in the psychodynamic tradition.
Originally, Freud postulated that symptoms developed from
repressing unacceptable material. From this perspective, a central
mechanism of change involved making the repressed unconscious
material conscious, especially regarding the historical
developmental origins (Freud, 1920). Since the relational turn,
this focus has shifted slightly, to specifically highlight the
importance of insight into internalized relational configurations
or models of self and other that developed from early experiences
with attachment figures (Greenberg and Mitchell, 1983).
This focus on change through insight into previously repressed
material, and insight into the effect of early relationships in
psychodynamic treatments closely links to the SAPT mechanisms
we have identified as re-experiencing of memories and personal
significance, insights, and meaningfulness. Psychodynamic treatments
would primarily use genetic interpretations into the developmental
origins of the difficulty, and transference interpretations into the
replaying of the relational patterns, to both identify and make
meaning out of this material. However, with SAPTs we could
see the initial process of insight being facilitated by the evocative
function of the substance. The traditional meaning-making process
of psychodynamic treatment would be highly relevant integrating
the evoked material during a subsequent integration stage.

SIMILARITY BETWEEN PRIMARY
MECHANISMS OF CHANGE IN VARIOUS
FORMS OF PSYCHOTHERAPY AND
MECHANISMS OF CHANGE IN SAPT
Some of the mechanisms presented in the SAPT literature
may also overlap with putative mechanisms of change posited
in the non-SAPT psychotherapy literature. In this section
we will relate the SAPT mechanisms to four key putative
mechanisms, each highlighted as a central change mechanism
by one of the major psychotherapy traditions: insight, cognitive
restructuring, mindfulness, and experiencing.
Even though there has been a temporal shift from Freudian
techniques to humanistic orientations (Grof, 2000), most of
the therapies in the first wave of psychedelic research applied
historically dominant psychoanalytic models (Roseman et al.,
2018). Additionally, there have been case studies including use
of exposure therapy (Costello, 1964), arguments for the
application of learning theory for behavioral re-programming
(Grieco and Bloom, 1981), and comparisons between approaches
used in indigenous cultures using Ayahuasca and transpersonal,
depth psychological, and parapsychological approaches and
interpretations (Andritzky, 1989).

Frontiers in Psychology | www.frontiersin.org

Cognitive Restructuring in Cognitive
Therapies

The central putative mechanism associated with Cognitive
Therapy is changing beliefs through reasoning, or cognitive
restructuring (Ellis, 1962; Beck, 1976). This mechanism has
primarily been targeted by disputation (Ellis, 1962) and Socratic
dialogues (Beck, 1976), in which people are lead to examine
their beliefs through open questioning and evaluating evidence.
This mechanism overlaps with what we have identified here
as reconditioning and perspective-shifts and cognitive flexibility.
While clearly, the initial shifts in SAPT come from substance
induced evocation, not through reasoning processes, but the
overlap of the identified mechanisms suggests that they may
shift a common mechanism. This also implies that standard
cognitive techniques may be relevant to consolidate the
restructuring and perspective shifts during the integration stage
of SAPTs.

8

July 2021 | Volume 12 | Article 617224

Thal et al.

Therapeutic Preset for Substance-Assisted Psychotherapy

Mindfulness in Third Wave Behavioral
Therapies

to the Rogerian relational conditions could be facilitated by
some substances, such as MDMA (Thal and Lommen, 2018).
The experiencing mechanism also seems closely tied to the
SAPT mechanism we have identified as personal significance,
insights, and meaningfulness, given that emotions inform about
things that are personally significant and meaningful. The SAPT
mechanism of reassessment of memories, could also be considered
a subset of the experiencing construct, given the memories
that are often referenced as being reassessed therapeutically in
SAPT tend to be emotionally salient and development significant
memories. These overlaps have lead for some to argue that
substances such as MDMA which functions to enhance the
sense of connection, meaningfulness and processing of emotions,
make it a natural adjunct for experiential therapies such as
emotion focused couples therapy (Almond and Allan, 2019).
There, awe and peak-experiences potentially amplify emotional
signals such as compassion to everything as well as fear.
Whilst the other therapeutic modalities seemed to
be technically suited to the integration stage of SAPTs; the
humanistic-experiential techniques most closely relate to those
that have been described for the administration stage. For
example, the current treatment-model for MDMA-assisted
psychotherapy for PTSD (Mithoefer, 2017) and some trials for
depression and anxiety (Carhart-Harris et al., 2016; Griffiths
et al., 2016; Roseman et al., 2018; Palhano-Fontes et al., 2019)
suggest a framework-free and predominantly non-directive and
client-centered approach seems especially relevant for SAPTs,
given the substances function to elicit relevant material. Therefore
a process following stance, as is typical in humanistic-experiential
therapies, seems the appropriate for this stage of therapy, and
that content directive therapeutic techniques could interfere
the substances eliciting function. The non-directive approach
of MDMA-assisted psychotherapy can empower clients to
understand and resolve problems in their lives on their own.
This may be reflected in enhanced measures of personal strength
and sense of possibility (Gorman et al., 2020) and qualitative
reports suggesting that clients prefer non-directive approaches
(Watts et al., 2017).

There are theoretical affinities between TWBTs (Hayes et al.,
1999; Segal et al., 2002) and psychedelic therapy, such as
their common root in contemplative spiritual practices, and
the development of mindfulness as a putative mechanism
of action (Soler et al., 2016, 2018; Smigielski et al., 2019).
In TWBT, the psychological state of mindfulness is developed
primarily through the practice of mindfulness techniques,
such as imagining thoughts on a leaf in a stream, and
meditation. While achieved through a different method, the
resulting state of mindfulness may be similar to the state
observed after the ingestion of psychedelics (Soler et al.,
2016). This synergy suggests that mindfulness, acceptance,
and meditation practices, like those included in TWBTs could
be used to sustain the state of mindfulness during the
integration stage of SAPTs (Walsh and Thiessen, 2018;
Sloshower et al., 2020; Wolff et al., 2020).

Therapeutic Relationship Conditions and
Experiencing in Humanistic-Experiential
Therapies

Humanistic-experiential therapies, such as Client-centered
(Rogers, 1966), Gestalt (Perls et al., 1951), and Emotion-Focused
Therapy (Greenberg and Johnson, 1988; Greenberg et al., 1993)
have emphasized two key change mechanisms – the therapeutic
relationship conditions and client experiencing – as central to
the psychotherapeutic change. Rogers (1959) posited that when
someone perceives that others’ positive regard for them is
conditional, then they develop “conditions of worth” reflecting
how they need to be in order to be accepted. Symptoms then
manifest from needing to distort experience to be congruent
with these conditions of worth. From this perspective, healing
and growth can occur when therapeutic relationship conditions,
including empathy, unconditional positive regard, and congruence
(Rogers, 1957), mean that a client does not need to defensively
distort their experience to be accepted. Thus, it is the therapist
providing the relational conditions, as the soil for a seed, that
would allow a client to change.
The second change mechanism is client experiencing, which
is that healing comes from accessing, feeling and symbolizing
the previously distorted or disavowed emotions. In recent
versions of experiential theory, this has been described as
“changing emotion with emotion,” such that accessing previously
disavowed emotions is what changes the problematic emotions.
For example, shame could be changed by accessing assertive
anger or compassion (Greenberg, 2015). This requires the safety
provided by therapeutic conditions as a necessary prerequisite,
but also then suggests that actively directing clients towards
their emotional experience through internal focusing (Gendlin,
1996), or through the use of evocative imagery and enactment
tasks, such as chairwork (Greenberg et al., 1993; Perls, 1996),
further facilitates the change process.
These two mechanisms may also overlap with some of the
identified SAPT mechanisms, as well as the technique suggestions
for conducting SAPT. Firstly the perception and receptiveness
Frontiers in Psychology | www.frontiersin.org

Synergistic Therapeutic Mechanisms

Nielson and Guss (2018) outline similarities between psychedelic
therapy, mindfulness-based interventions, and psychoanalysis.
First, they all evoke altered states of consciousness allowing
inaccessible parts of the self to be retrieved. As mentioned
above, increased cognitive flexibility (i.e., increased bottom-up
prediction errors) induced by psychedelics may result in
de-patterning and perspective-shifts, increased insights, and
personal meaningful re-experiencing of memories. Second, the
therapist gives shape and direction to the course of the therapy,
but has limited control over the tools for healing which are
inherited in the client’s mind (Freud, 1912; Walsh and Grob,
2006; McCown et al., 2010). Third, the therapist’s personal
perception, presence, and experience during the therapeutic
sessions is used to guide the client and the process (Rubin,
1985; Kabat-Zinn, 2003; Phelps, 2017). In turns, the creation
of the ideal set and setting is supported by the therapist, to
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facilitate an altered state of consciousness that supports the
unfolding of the inner healing capacities of the client
(Nielson and Guss, 2018).

Palhano-Fontes et al. (2019), for instance, reported that five
participants with TRD and comorbid borderline personality
disorder who received Ayahuasca showed significant decreases
in clinical symptomps of depression 7 days post treatment.
However, treatment of comorbid disoders introduces unique
challenges in terms of diagnoses and screening (e.g., Shivani
et al., 2002; Wu and Fang, 2014), effective treatments (e.g.,
Roberts et al., 2015), and potential side-effects (e.g., with bipolarand/or psychotic disoders). More research regarding the potential
harms and benefits of SAPT for the treatment for comorbid
disorders and potential transdiagnostic approaches (Dalgleish
et al., 2020) is needed. Another limitation pertains to TRD:
many forms of TRD belong to the bipolar spectrum and some
have argued that treatment-resistant unipolar depression may
be considered a prodromal phase of bipolar disorder (Dudek
et al., 2010). Non-diagnosed bipolarity was further identified
as an independent risk factor for treatment resistance in TRD
(Bennabi et al., 2015). The diagnostic distinction between unipolar
depression and bipolar depression is of utmost importance
because antidepressant medication, commonly used for the
treatment of unipolar depression, may induce mania, hypomania,
insomnia, and irritability in those with bipolar depression
(Ghaemi et al., 2000; Pacchiarotti et al., 2013). Since some
people with bipolar diosder may experience psychotic episodes
after substance use (Starzer et al., 2018), it is listed as a
contraindication for most clinical investiations applying SAPT.
However, the safety and efficacy of psilocybin is currently
investigated for those with biploar disorder type 2.1 For the
treatment of TRD with SAPT, the identification of unipolar
and bipolar depression (especially bipolar depression type 1)
has to be closely monitored during the screening process and
more research is needed to improve screening for and treatment
of bipolar depression with SAPT.
We have outlined the mechanisms of change in SAPT
that have been identified in the literature and their similarity
to mechanisms of change described in traditional psychotherapy.
Through this analysis it was highlighted that different traditional
therapeutic approaches and techniques might be effectively
combined with and related to certain stages of SAPT and
different therapeutic outcomes. The purposeful application
and investigation of different approaches and techniques and
their relation to therapeutic outcomes should be assessed in
the future.
Furthermore, current literature may suggest that like traditional
psychotherapy, the therapeutic effect of SAPT may not only
be mediated by specific substances, therapeutic orientations,
or models per se; rather the therapeutic effect may depend
on factors like the therapeutic- and interpersonal relationship,
empathy, therapeutic presence, and unconditional acceptance
(Asay and Lambert, 1999; Geller and Greenberg, 2012; Wampold,
2015). Despite the validation of current standardized models,
future research should investigate these intersecting variables
across models, as well. Careful attention to pre-screening,
contextual factors (i.e., set and setting), substance and dosage,
as well as preparation (intentions) and integration (meaning)

Moving Towards an Incorporation
of Various Frameworks

In general, psychotherapy usually produces similar outcomes
across different orientations and it might be more effective to
fit and adapt the intervention to the particular client’s needs
(APA, 2012). Likewise, the extensive review of the literature
suggests that the effectiveness or reported benefits of SAPT
might not be due to the theoretical orientation of the therapist
per se, but rather derived from important similarities and
overlap between different schools of psychotherapy and dependent
on intra- and interpersonal variables (Frank and Frank, 1991;
Asay and Lambert, 1999; Wampold, 2015). Altered states of
consciousness often allow clients to employ state alteration
(Jiang et al., 2017) to change their point of view on an issue
(as in cognitive restructuring with hypnosis; Spiegel, 2013) or
experience negative events and let feelings pass without struggling
against them (as in mindfulness; Paulson et al., 2013). Further,
memory reactivation, reconsolidation, and reintegration (Lane
et al., 2015) during SAPT may aid therapeutic change. This
can be aided by CBT, interpersonal psychotherapy, psychodynamic
psychotherapy, emotion-focused-therapy, or hypnosis and
mindfulness (Lane et al., 2015; Spiegel, 2016). Providing a
framework in which the client’s problems can be understood
may be more important than a particular orientation (Ludwig
and Levine, 1965a).

CONCLUSION
In this narrative review, we have outlined valuable prerequisites
for thepsists who are considering engaging in SAPT that
comprise a preset of knowledge and considerations for
investigations and interventions. In doing so, several approaches
to SAPT have been outlined to illustrate how literature on
various schools of psychotherapy can be linked to the literature
we reviewed about SAPT. Thereby, similarities across models
and therapeutic orientations were highlighted. From this review,
it may be suggested that various schools of psychotherapy
could be incorporated into the development of respective
therapeutic models. We hope this provides a basis for the
development and adaptation of future investigations, therapeutic
models, training programs for therapists, and those interested
in the therapeutic potential of SAPT.
There are limitations to the findings outlined above since
the mechanisms of action and therapeutic models depicted in
this article have yet to be validated and further investigation
employing rigorous research is required. Moreover, comorbidity
is a common issue with substance use, anxiety, mood disorders,
and post-traumatic stress (Rytwinski et al., 2013; Lai et al.,
2015) – the very conditions for which current clinical
investigations of SAPT are being conducted. It may be argued
that comorbidity between disorders could facilitate the therapeutic
application of SAPT across disorders (Breeksema et al., 2020).
Frontiers in Psychology | www.frontiersin.org
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of the experience are commonalities across different models
of SAPT (Bogenschutz and Ross, 2016) and thought to be key
determinants of the therapeutic outcome (Bogenschutz and
Forcehimes, 2017). Combining these key determinants with
common factors that are important for producing positive
treatment outcomes in psychotherapy such as therapeutic
relationship, empathy, expectations, and therapist differences
(Wampold, 2015), may be important to allow for the broader
application of SAPT across different models of psychotherapy
(that share these common factors). Consequently, future studies
should, as a standard, include valid measures of the therapeutic
relationship (Horvath and Greenberg, 1989), therapeutic presence
(Geller et al., 2010), empathy (Dziobek et al., 2008), expectations,
and personality factors of therapist and client (e.g., Benjamin
et al., 2006) in order to assess their potential influence on
the treatment outcome. Eventually, it is conceivable that certain
substances (or their combination) will be more compatible

with certain therapeutic approaches and/or clinical targets,
synergistically fostering particular mechanisms. Thus far, no
controlled studies have been conducted in which different
models of psychotherapy have been compared using the same
compound, or in which different substances have been compared
using the same models of psychotherapy. More research is
needed to determine which substances and forms of therapy
may be effectively combined.
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